Post-operative management of primary glioblastoma multiforme in patients over 60 years of age

Borbála Daróczi, Erika Szántó, J. Tóth, P. Barzó, L. Bognár, Gyula Bakó, J. Szántó, Petra Mózes, K. Hideghéty

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and purpose - Optimal treatment for elderly patients with glioblastoma multiforme is not well defined. We evaluated the efficacy of post-operative radiotherapy with or without concomitant and/or adjuvant temozolomide in patients aged ≥60 years to assess survival and identify prognostic factors of survival. Methods - A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged ≥60 years treated with post-operative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions. Prognostic factors were determined by univariate and multivariate analyses. Results - Of 75 study participants (54.7% male; median age at first diagnosis, 65.1 years), 29 (38.7%) underwent gross total resection, whereas others underwent partial resection or biopsy only. All but 1 patient received radiotherapy. Twenty patients received concomitant temozolomide only. Adjuvant temozolomide (1-50 cycles) was administered in 42 patients; 16 received ≥6 cycles. Median overall survival was 10.3 months. One- and 2-year overall survival rates were 42.6% and 6.7%, respectively. Median progression-free survival was 4.1 months. Radiochemotherapy was generally well tolerated. Median overall survival was 15.3 and 29.6 months for patients who received 6-12 cycles and > 12 cycles of adjuvant temozolomide, respectively. There were no significant differences in overall survival between age groups (60-64, 65-69, and ≥70 years). Adjuvant temozolomide, Karnofsky performance status ≥70, and additional surgery after progression were significant prognostic factors of longer overall survival (p

Original languageEnglish
Pages (from-to)391-398
Number of pages8
JournalIdeggyógyászati szemle
Volume66
Issue number11-12
Publication statusPublished - 2013

Fingerprint

temozolomide
Glioblastoma
Survival
Radiotherapy
Disease-Free Survival
Karnofsky Performance Status
Chemoradiotherapy
Survival Analysis
Multivariate Analysis
Survival Rate
Age Groups

Keywords

  • Adjuvant
  • Elderly
  • Glioblastoma
  • Neurosurgery
  • Radiochemotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Post-operative management of primary glioblastoma multiforme in patients over 60 years of age. / Daróczi, Borbála; Szántó, Erika; Tóth, J.; Barzó, P.; Bognár, L.; Bakó, Gyula; Szántó, J.; Mózes, Petra; Hideghéty, K.

In: Ideggyógyászati szemle, Vol. 66, No. 11-12, 2013, p. 391-398.

Research output: Contribution to journalArticle

@article{9130245cd5ba4cc385f4fd0a020a9da7,
title = "Post-operative management of primary glioblastoma multiforme in patients over 60 years of age",
abstract = "Background and purpose - Optimal treatment for elderly patients with glioblastoma multiforme is not well defined. We evaluated the efficacy of post-operative radiotherapy with or without concomitant and/or adjuvant temozolomide in patients aged ≥60 years to assess survival and identify prognostic factors of survival. Methods - A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged ≥60 years treated with post-operative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions. Prognostic factors were determined by univariate and multivariate analyses. Results - Of 75 study participants (54.7{\%} male; median age at first diagnosis, 65.1 years), 29 (38.7{\%}) underwent gross total resection, whereas others underwent partial resection or biopsy only. All but 1 patient received radiotherapy. Twenty patients received concomitant temozolomide only. Adjuvant temozolomide (1-50 cycles) was administered in 42 patients; 16 received ≥6 cycles. Median overall survival was 10.3 months. One- and 2-year overall survival rates were 42.6{\%} and 6.7{\%}, respectively. Median progression-free survival was 4.1 months. Radiochemotherapy was generally well tolerated. Median overall survival was 15.3 and 29.6 months for patients who received 6-12 cycles and > 12 cycles of adjuvant temozolomide, respectively. There were no significant differences in overall survival between age groups (60-64, 65-69, and ≥70 years). Adjuvant temozolomide, Karnofsky performance status ≥70, and additional surgery after progression were significant prognostic factors of longer overall survival (p",
keywords = "Adjuvant, Elderly, Glioblastoma, Neurosurgery, Radiochemotherapy",
author = "Borb{\'a}la Dar{\'o}czi and Erika Sz{\'a}nt{\'o} and J. T{\'o}th and P. Barz{\'o} and L. Bogn{\'a}r and Gyula Bak{\'o} and J. Sz{\'a}nt{\'o} and Petra M{\'o}zes and K. Hidegh{\'e}ty",
year = "2013",
language = "English",
volume = "66",
pages = "391--398",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "11-12",

}

TY - JOUR

T1 - Post-operative management of primary glioblastoma multiforme in patients over 60 years of age

AU - Daróczi, Borbála

AU - Szántó, Erika

AU - Tóth, J.

AU - Barzó, P.

AU - Bognár, L.

AU - Bakó, Gyula

AU - Szántó, J.

AU - Mózes, Petra

AU - Hideghéty, K.

PY - 2013

Y1 - 2013

N2 - Background and purpose - Optimal treatment for elderly patients with glioblastoma multiforme is not well defined. We evaluated the efficacy of post-operative radiotherapy with or without concomitant and/or adjuvant temozolomide in patients aged ≥60 years to assess survival and identify prognostic factors of survival. Methods - A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged ≥60 years treated with post-operative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions. Prognostic factors were determined by univariate and multivariate analyses. Results - Of 75 study participants (54.7% male; median age at first diagnosis, 65.1 years), 29 (38.7%) underwent gross total resection, whereas others underwent partial resection or biopsy only. All but 1 patient received radiotherapy. Twenty patients received concomitant temozolomide only. Adjuvant temozolomide (1-50 cycles) was administered in 42 patients; 16 received ≥6 cycles. Median overall survival was 10.3 months. One- and 2-year overall survival rates were 42.6% and 6.7%, respectively. Median progression-free survival was 4.1 months. Radiochemotherapy was generally well tolerated. Median overall survival was 15.3 and 29.6 months for patients who received 6-12 cycles and > 12 cycles of adjuvant temozolomide, respectively. There were no significant differences in overall survival between age groups (60-64, 65-69, and ≥70 years). Adjuvant temozolomide, Karnofsky performance status ≥70, and additional surgery after progression were significant prognostic factors of longer overall survival (p

AB - Background and purpose - Optimal treatment for elderly patients with glioblastoma multiforme is not well defined. We evaluated the efficacy of post-operative radiotherapy with or without concomitant and/or adjuvant temozolomide in patients aged ≥60 years to assess survival and identify prognostic factors of survival. Methods - A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged ≥60 years treated with post-operative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions. Prognostic factors were determined by univariate and multivariate analyses. Results - Of 75 study participants (54.7% male; median age at first diagnosis, 65.1 years), 29 (38.7%) underwent gross total resection, whereas others underwent partial resection or biopsy only. All but 1 patient received radiotherapy. Twenty patients received concomitant temozolomide only. Adjuvant temozolomide (1-50 cycles) was administered in 42 patients; 16 received ≥6 cycles. Median overall survival was 10.3 months. One- and 2-year overall survival rates were 42.6% and 6.7%, respectively. Median progression-free survival was 4.1 months. Radiochemotherapy was generally well tolerated. Median overall survival was 15.3 and 29.6 months for patients who received 6-12 cycles and > 12 cycles of adjuvant temozolomide, respectively. There were no significant differences in overall survival between age groups (60-64, 65-69, and ≥70 years). Adjuvant temozolomide, Karnofsky performance status ≥70, and additional surgery after progression were significant prognostic factors of longer overall survival (p

KW - Adjuvant

KW - Elderly

KW - Glioblastoma

KW - Neurosurgery

KW - Radiochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84891909627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891909627&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 391

EP - 398

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 11-12

ER -